Lacosamida Cinfa

Lacosamide, the active ingredient in Lacosamida Cinfa, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamida Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug used to control seizure activity in the central nervous system.

Partial‑onset seizures: reduces the frequency and severity of focal seizures. Epilepsy: provides adjunctive therapy for patients with refractory epilepsy. Adjunctive therapy: used alongside other antiepileptic medications to improve overall seizure control.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Diplopia (double vision) - Somnolence

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Cardiac arrhythmias or PR‑interval prolongation - Hypersensitivity reactions (anaphylaxis) - Liver enzyme elevations - Severe respiratory depression (rare).

When prescribing Lacosamide, consider the following precautions.

Renal impairment: adjust dose in patients with reduced kidney function. Hepatic impairment: monitor liver function and consider dose adjustment. Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation. Pregnancy: safety not established; weigh benefits against potential risks. Driving and operating machinery: caution due to possible dizziness or somnolence. Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Lacosamide can interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital) may markedly reduce lacosamide plasma levels. - Concurrent use with other sodium‑channel blockers (e.g., lamotrigine) can increase risk of cardiac conduction abnormalities. - QT‑prolonging agents may exacerbate cardiac rhythm effects.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: efficacy may be decreased, requiring additional contraceptive measures. - Alcohol: may enhance central nervous system depression. - Other antiepileptic drugs: monitor for additive side‑effects such as dizziness or fatigue.